Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 71.04% is 180% above its 5-year average of -89.08%, near the high end of its 5-year range (-931.46%–71.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 122.97% above its 12-month average of -309.29%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 71.04%.
RETURN ON EQUITY (ROE)
71.04%
RETURN ON EQUITY (ROE) AVG TTM
-309.29%
RETURN ON EQUITY (ROE) AVG 3Y
-151.27%
RETURN ON EQUITY (ROE) AVG 5Y
-89.08%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+122.97%
CURRENT VS 3Y AVG
+146.96%
CURRENT VS 5Y AVG
+179.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+269.10%
vs the sector median at left
Liquidia Corporation
Market Cap
$2.35B
Return on Equity (ROE)
71.04%
TTM Avg
-309.29%
3Y Avg
-151.27%
5Y Avg
-89.08%
Market Cap
$2.34B
Return on Equity (ROE)
-84.78%
TTM Avg
-42.91%
3Y Avg
-54.25%
5Y Avg
-44.36%
Market Cap
$2.33B
Return on Equity (ROE)
15.63%
TTM Avg
16.66%
3Y Avg
16.66%
5Y Avg
13.72%
Market Cap
$2.36B
Return on Equity (ROE)
41.39%
TTM Avg
43.71%
3Y Avg
5.79%
5Y Avg
-18.90%
Market Cap
$2.37B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
Market Cap
$2.29B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
Market Cap
$2.40B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.40B
Return on Equity (ROE)
-4.88%
TTM Avg
-20.16%
3Y Avg
-52.49%
5Y Avg
-49.61%
Market Cap
$2.42B
Return on Equity (ROE)
-38.17%
TTM Avg
-26.66%
3Y Avg
-25.50%
5Y Avg
23.47%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liquidia Corporation (LQDA) | $2.35B | 71.04% | -309.29% | -151.27% | -89.08% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | -84.78% | -42.91% | -54.25% | -44.36% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 15.63% | 16.66% | 16.66% | 13.72% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 41.39% | 43.71% | 5.79% | -18.90% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.37B | N/A | 9.38% | 9.38% | 9.38% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 18.14% | 20.16% | 28.24% | 15.58% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | -56.71% | -50.91% | -55.48% | -35.68% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -4.88% | -20.16% | -52.49% | -49.61% |
| Disc Medicine, Inc. (IRON)vs › | $2.42B | -38.17% | -26.66% | -25.50% | 23.47% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.24B | -37.82% | -53.05% | -23.57% | 8.38% |
ROE
71.0%
ROA
26.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 71.04% |
| 2026-03-31 | 20.54% |
| 2025-12-31 | -154.03% |
| 2025-09-30 | -552.55% |
| 2025-06-30 | -931.46% |
| 2025-03-31 | -257.14% |
| 2024-12-31 | -168.74% |
| 2024-09-30 | -108.10% |
| 2024-06-30 | -178.74% |
| 2024-03-31 | -124.84% |
| 2023-12-31 | -165.99% |
| 2023-09-30 | -119.95% |
| 2023-06-30 | -83.89% |
| 2023-03-31 | -45.10% |
| 2022-12-31 | -45.36% |
| 2022-09-30 | -48.45% |
| 2022-06-30 | -43.32% |
| 2022-03-31 | -74.63% |
| 2021-12-31 | -52.98% |
| 2021-09-30 | -53.59% |
| 2021-06-30 | -59.21% |
| 2021-03-31 | -86.08% |
| 2020-12-31 | -84.07% |
| 2020-09-30 | -89.10% |
| 2020-06-30 | -638.40% |
| 2020-03-31 | -223.26% |
| 2019-12-31 | -136.16% |
| 2019-09-30 | -218.82% |
| 2019-06-30 | -121.60% |
| 2019-03-31 | -105.57% |
| 2018-12-31 | -284.34% |
| 2018-09-30 | -126.51% |
